argenx(ARGX)将斥资至多11.5亿美元收购Unnatural Products 加码大环肽技术

金吾财讯
Nov 09

金吾财讯 | argenx SE(ARGX)宣布已达成最终协议,将收购此前已持有少数股权的生物技术公司Unnatural Products, Inc.(UNP)。交易完成后,UNP将成为argenx全资子公司,其位于美国加州圣克鲁斯的团队将继续主导肽发现工作。目前,该交易已获双方董事会批准,预计将于今年年底前正式完成。根据协议条款,该交易总潜在对价最高可达约11.5亿美元。其中包含5.5亿美元的现金预付款(使用现有现金储备),以及5.95亿美元的研发和监管里程碑后续付款。argenx首席执行官Karen Massey表示,将UNP尖端的大环肽(环状分子)发现平台与其自身的抗体工程技术相结合,具有高度互补性。这不仅将显著拓展公司在靶向新型生物学领域的研发边界,也为开发更具突破性的口服或长效药物奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10